Clinical Trials Logo

Clinical Trial Summary

Cholangitis is the most common postoperative complication of biliary atresia, with a reported incidence of 40-90%, which seriously affects the surgical effect, survival rate and the quality of life and prognosis of patients. Without of direct evidence, the diagnosis of cholangitis sometimes is difficult to make, thus most of them are diagnosed based on the symptoms of children. According to literature reports, different centers and regions have different diagnostic criteria for postoperative cholangitis after hepatic portoenterostomy, which has a great influence on the accuracy of the incidence rate and appropriate treatment of cholangitis, and also brings differences in the analysis of the causes and prognostic factors of cholangitis. Based on the above reasons, we used the Delphi method,in which worldwidely 48 experts participated in, to establish the diagnostic scoring system for postoperative cholangitis after biliary atresia. Now we aimed to verify the specificity and sensitivity of the new scoring system through clinical cases, in order to unify and standardize the diagnostic criteria and provide help for the diagnosis and treatment of cholangitis after biliary atresia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05464303
Study type Observational
Source Nanjing Children's Hospital
Contact Xie Hua, Dr
Phone +8613611573952
Email xiehua3955@126.com
Status Recruiting
Phase
Start date July 15, 2022
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03667534 - Dry Blood Spot Screening Test for Neonatal Cholestasis Patients
Completed NCT02652533 - Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia
Completed NCT01443572 - The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation N/A
Recruiting NCT04373941 - Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia Phase 2
Completed NCT01854827 - Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia Phase 1/Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Recruiting NCT05848310 - Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Recruiting NCT05072626 - High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
Completed NCT02292862 - Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation N/A
Completed NCT00294684 - A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy N/A
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Recruiting NCT04260503 - Gut Microbiome in Biliary Atresia
Not yet recruiting NCT06260566 - Tolerability of Enteral NAC in Infants Phase 1
Completed NCT01322386 - Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Phase 1
Recruiting NCT05909033 - Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure
Completed NCT03499249 - N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy Phase 2
Recruiting NCT00345553 - Biliary Atresia Study in Infants and Children
Recruiting NCT05521152 - Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Phase 3
Not yet recruiting NCT05783518 - Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant Recipients Phase 4
Not yet recruiting NCT06121375 - Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy Phase 2/Phase 3